Baron Financial Group’s Arcturus Therapeutics ARCT Stock Holding History

Baron Financial Group’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-100	Closed	-$1.57K	–	60
2022 Q2	$1.57K	Hold	100	–	–	﹤0.01%	191
2022 Q1	$2.7K	Hold	100	–	–	﹤0.01%	195
2021 Q4	$3.7K	Hold	100	–	–	﹤0.01%	193
2021 Q3	$4.78K	Hold	100	–	–	﹤0.01%	193
2021 Q2	$3.38K	Hold	100	–	–	﹤0.01%	210
2021 Q1	$4.13K	Hold	100	–	–	﹤0.01%	205
2020 Q4	$4.34K	Hold	100	–	–	﹤0.01%	213
2020 Q3	$4.29K	Buy	+100	New	+$4.96K	﹤0.01%	213

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Baron Financial Group's ARCT Position: Q3 2022 in Review

Baron Financial Group sold out of Arcturus Therapeutics (ARCT) in Q3 2022, closing a stake of 100 shares — an estimated $1.57K sold.

Baron Financial Group first reported a position in ARCT in Q3 2020 and held it in 8 quarters. The position peaked at $4.78K in Q3 2021. 116 funds tracked by Wall St. Rank hold ARCT as of Q3 2022.

Baron Financial Group reported no remaining Arcturus Therapeutics position as of Q3 2022 after selling out during the quarter.
Baron Financial Group sold 100 Arcturus Therapeutics shares in Q3 2022, an estimated $1.57K.
Baron Financial Group first reported a position in Arcturus Therapeutics in Q3 2020 and held it in 8 quarters.
Baron Financial Group's Arcturus Therapeutics position peaked at $4.78K in Q3 2021.
116 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2022.

Based on Baron Financial Group's 13F filing for Q3 2022, filed 3 Nov 2022.